Factors affecting levels of circulating cell-free fetal DNA in maternal plasma and their implications for noninvasive prenatal testing
Authors:
- 14 July 2015
- journal article
- research article
- Published by Wiley in Prenatal Diagnosis
- Vol. 35 (8) , 816-822
Abstract
Objective Sufficient fetal DNA in a maternal plasma sample is required for accurate aneuploidy detection via noninvasive prenatal testing, thus highlighting a need to understand the factors affecting fetal fraction. Method The MaterniT21TM PLUS test uses massively parallel sequencing to analyze cell‐free fetal DNA in maternal plasma and detect chromosomal abnormalities. We assess the impact of a variety of factors, both maternal and fetal, on the fetal fraction across a large number of samples processed by Sequenom Laboratories. Results The rate of increase in fetal fraction with increasing gestational age varies across the duration of the testing period, and is also influenced by fetal aneuploidy status. Maternal weight trends inversely with fetal fraction, and we find no added benefit from analyzing BMI or blood volume instead of weight. Strong correlations exist between fetal fractions from aliquots taken from the same patient at the same blood draw, and also at different blood draws. Conclusion While a number of factors trend with fetal fraction across the cohort as a whole, they are not the sole determinants of fetal fraction. In this study, the variability for any one patient does not appear large enough to justify postponing testing to a later gestational age.Keywords
Funding Information
- Sequenom, Inc.
- Sequenom Laboratories
This publication has 25 references indexed in Scilit:
- High-Throughput Massively Parallel Sequencing for Fetal Aneuploidy Detection from Maternal PlasmaPLOS ONE, 2013
- Noninvasive prenatal aneuploidy testing of chromosomes 13, 18, 21, X, and Y, using targeted sequencing of polymorphic lociPrenatal Diagnosis, 2012
- Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18American Journal of Obstetrics and Gynecology, 2012
- DNA sequencing of maternal plasma to identify Down syndrome and other trisomies in multiple gestationsPrenatal Diagnosis, 2012
- Fetal Fraction in Maternal Plasma Cell-Free DNA at 11–13 Weeks’ Gestation: Effect of Maternal and Fetal FactorsFetal Diagnosis and Therapy, 2012
- Genome-Wide Fetal Aneuploidy Detection by Maternal Plasma DNA SequencingObstetrics & Gynecology, 2012
- Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18American Journal of Obstetrics and Gynecology, 2012
- DNA sequencing of maternal plasma to detect Down syndrome: An international clinical validation studyGenetics in Medicine, 2011
- Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity studyBMJ, 2011
- Presence of fetal DNA in maternal plasma and serumThe Lancet, 1997